Clinical Trials Browser

Triple Negative Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2 Recruiting

220 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Phase 2 Recruiting

111 enrolled

Breast

Breast Neoplasms

NCT07378306 2026-01-30

FACT-TN

Phase 2 Not yet recruiting

80 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Phase 2 Recruiting

35 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3 Recruiting

400 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07256964 2025-12-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Phase 2 Not yet recruiting

216 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07244874 2025-11-24

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Phase 2 Not yet recruiting

41 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

414 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06371274 2025-08-12

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Phase NA Recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06611813 2025-08-12

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Phase 2 Not yet recruiting

125 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2 Recruiting

27 enrolled

Breast

Breast Neoplasms

NCT06991790 2025-05-28

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06977893 2025-05-18

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Phase 3 Recruiting

194 enrolled

Breast

Breast Neoplasms

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06878625 2025-03-25

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Phase 2 Recruiting

138 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

NEOTRIO-2

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

FACT-TN

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

NeoHunter

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer